Pharmaceuticals

Androgen Deprivation Therapy Market Forecast: How Big Will It Be by 2030?

February 12, 2026February 12, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the androgen deprivation therapy market from 2026–2035 with trusted insights from The Business Research Company

What growth pattern is forecast for the Androgen Deprivation Therapy Market size between 2026 and 2035?

The androgen deprivation therapy market has demonstrated strong growth in recent years. It is anticipated to increase from $8.31 billion in 2025 to $8.83 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.3%. This historical expansion can be attributed to factors such as limited treatment options for prostate cancer, a reliance on conventional surgery, the slow adoption of injectable therapies, low patient awareness of androgen deprivation therapy, and restricted availability of advanced therapies.

The androgen deprivation therapy market is poised for significant expansion in the coming years, with projections indicating it will reach a value of $11.1 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.9%. This anticipated growth throughout the forecast period stems from factors such as the creation of new anti-androgen medications, increased financial commitment to gene and immunotherapies, an expanding elderly male demographic, the proliferation of specialized clinics and hospital oncology units, and the incorporation of digital monitoring and telehealth technologies. Key trends anticipated during this period encompass a greater acceptance of LHRH agonists and antagonists, more prevalent application of combination and targeted treatments, an increase in minimally invasive surgical interventions, a heightened emphasis on individualized and age-appropriate therapies, and improved monitoring and subsequent care for individuals with prostate cancer.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25692&type=smp

Which Drivers Are Impacting Market Performance In The Androgen Deprivation Therapy Market?

The rising prevalence of prostate cancer is anticipated to propel the expansion of the androgen deprivation therapy market in the foreseeable future. This cancer develops in the prostate gland, an organ in the male reproductive system that produces seminal fluid. Its occurrence is on the rise primarily because people are living longer, as advanced age significantly boosts the likelihood of developing the condition. Androgen deprivation therapy (ADT) serves as a key treatment method for prostate cancer, designed to reduce androgen levels that stimulate tumor growth. It is often employed in advanced or metastatic stages to slow the disease’s progression. For example, a report from Prostate Cancer UK, a UK-based prostate cancer research, awareness, and support organization, stated in January 2025 that prostate cancer diagnoses in England grew from 50,751 cases in 2022 to 55,033 cases in 2023, demonstrating a distinct uptick in annual incidence. Consequently, the escalating incidence of prostate cancer is a significant factor boosting the androgen deprivation therapy market’s growth.

What Segment Types Are Examined In The Androgen Deprivation Therapy Market?

The androgen deprivation therapy market covered in this report is segmented –

1) By Type: Medicine, Surgery, Other Types

2) By Route Of Administration: Injectable, Oral

3) By Patient Demographics: Men Aged 40-60, Men Aged 61-75, Men Above 75

4) By Application: Prostate Cancer, Other Applications

5) By End-User: Hospitals, Specialty Clinics, Other End-Users

Subsegments:

1) By Medicine: LHRH Agonists, LHRH Antagonists, Anti-Androgens, CYP17 Inhibitors, Steroidal Anti-Androgens, Non-Steroidal Anti-Androgens, Estrogen-Based Therapies, Combination Therapies

2) By Surgery: Bilateral Orchiectomy, Subcapsular Orchiectomy, Simple Orchiectomy

3) By Other Types: Radiopharmaceutical Therapy, Gene Therapy, Immunotherapy, Targeted Therapy, Cryotherapy, High-Intensity Focused Ultrasound (HIFU

Which Innovation Trends Are Advancing Developments Within The Androgen Deprivation Therapy Market?

Leading enterprises operating within the androgen deprivation therapy (ADT) market are concentrating on developing advanced solutions, such as oral androgen receptor inhibitors (ARIs), to offer more convenient, tolerable, and effective treatment options for patients with prostate cancer. These oral ARIs are targeted therapies designed to directly block androgen receptor activity in prostate cancer cells, thereby preventing tumor growth without the need for frequent clinic-administered hormone-suppressing injections. For instance, in June 2025, Bayer AG, a Germany-based multinational pharmaceutical company, obtained US Food and Drug Administration (FDA) approval for Nubeqa (darolutamide), an oral ARI utilized in conjunction with ADT for treating metastatic hormone-sensitive prostate cancer (mHSPC). Nubeqa, which aims to improve clinical outcomes and patient quality of life, inhibits androgen receptor signaling with high binding affinity, shows minimal blood–brain barrier penetration to restrict central nervous system side effects, and, according to the Phase III ARANOTE trial, achieved a 46% reduction in the risk of radiological progression or death compared to placebo plus ADT.

Who Are The Prominent Global Companies Shaping The Androgen Deprivation Therapy Market Landscape?

Major companies operating in the androgen deprivation therapy market are Johnson & Johnson Services Inc., Astellas Pharma Inc., Ipsen S.A., Ferring Pharmaceuticals SA, Tolmar Pharmaceuticals Inc., Pfizer Inc., Novartis AG, Dr. Reddy’s Laboratories Ltd., Orion Corporation, Besins Healthcare S.A., Veru Inc., Kintor Pharmaceutical Limited, Foresee Pharmaceuticals Co. Ltd., Lawley Pharmaceuticals Pty Ltd., AbbVie Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Lupin Limited, Cipla Ltd., Accord Healthcare Ltd., Mylan N.V. (Viatris), Zydus Lifesciences Ltd., Apotex Inc., Amneal Pharmaceuticals LLC, Glenmark Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Aurobindo Pharma Ltd., Alvogen Inc., BCN Peptides SA, Chugai Pharmaceutical Co. Ltd., Sumitomo Pharma Co. Ltd.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/androgen-deprivation-therapy-global-market-report

Which Geographic Areas Are Emerging As Strong Markets For The Androgen Deprivation Therapy Market?

North America was the largest region in the androgen deprivation therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the androgen deprivation therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Androgen Deprivation Therapy Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=25692&type=smp

Browse Through More Reports Similar to the Global Androgen Deprivation Therapy Market 2026, By The Business Research Company

Hormone Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/hormone-therapy-global-market-report

Testosterone Replacement Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/testosterone-replacement-therapy-global-market-report

Drugs For Hormonal Replacement Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/drugs-for-hormonal-replacement-therapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795